Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Renal impairment in type 2 diabetes limits available glucose-lowering treatment options. This trial was conducted to establish the efficacy and safety of liraglutide as an add-on to existing glucose-lowering medications in patients with inadequately controlled type 2 diabetes and moderate renal impairment. RESEARCH DESIGN AND METHODS: In this 26-week, double-blind trial, 279 patients with HbA1c 7–10%, BMI 20–45 kg/m2, and moderate renal impairment (estimated glomerular filtration rate [eGFR] 30–59 mL/min/1.73 m2; MDRD) were randomized (1:1) to once-daily liraglutide 1.8 mg (n = 140) or placebo (n = 139). RESULTS: The estimated treatment difference in HbA1c from baseline to week 26 was −0.66% (−7.25 mmol/mol) (95% CI −0.90 to −0.43 [−9.82 to −4.69]), P < 0.0001). Fasting plasma glucose decreased more with liraglutide (−1.22 mmol/L [−22.0 mg/dL]) than with placebo (−0.57 mmol/L [−10.3 mg/dL], P = 0.036). There was a greater reduction in body weight with liraglutide (−2.41 kg) than with placebo (−1.09 kg, P = 0.0052). No changes in renal function were observed (eGFR relative ratio to baseline: −1% liraglutide, +1% placebo; estimated treatment ratio [ETR] 0.98, P = 0.36). The most common adverse events were gastrointestinal (GI) adverse effects (liraglutide, 35.7%; placebo, 17.5%). No difference in hypoglycemic episodes was observed between treatment groups (event rate/100 patient-years of exposure: liraglutide, 30.47; placebo, 40.08; P = 0.54). The estimated ratio to baseline for lipase was 1.33 for liraglutide and 0.97 for placebo (ETR 1.37, P < 0.0001). CONCLUSIONS: Liraglutide did not affect renal function and demonstrated better glycemic control, with no increase in hypoglycemia risk but with higher withdrawals due to GI adverse events than placebo in patients with type 2 diabetes and moderate renal impairment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Unlike the LEADER and SCALE trials, in the LIRA-RENAL trial liraglutide was found to be ineffective in improving renal outcomes in a sample of 279 diabetic patients with moderate CKD (eGFR 30–59 mL/min/1.73 m2).”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [44]
In the citing paper
“The authors found no difference in terms of eGFR and UACR compared with placebo after 26 weeks of treatment [44].”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [44]
Citations
Cites
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Levey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y. (., Hendriksen, S., Kusek, J. W., & Van Lente, F. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-4-200608150-00004 · Cited by 5,725 · cited 1×
“Safety assessments included adverse events (AEs), change from baseline to Week 26 in renal function (eGFR [MDRD] (19), urinary albumin:creatinine ratio [UACR]), amylase, lipase and pulse rate.”
(2013) · Kidney International Supplements · doi:10.1038/kisup.2012.73 · Cited by 3,206
Gerstein, H. C. (2001) · JAMA · doi:10.1001/jama.286.4.421 · Cited by 2,440 · cited 1×
“Albuminuria is not only a marker for kidney damage but it is also a cardiovascular risk factor (33,34).”
BackgroundBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Research works printed but not linked: 1
- Scott, 2014, Efficacy and safety of liraglutide versus placebo by eGFR subgroup in subjects with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized trial (Abstract), J Am Soc Nephrol, 25, 75A
Cited by
Items 101–200 of 234
Ngoc, N. B., Nguyen, L., Mital, S., Bugden, S., & Nguyen, H. V. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15009 · Cited by 24
“Meanwhile, the other two studies suffered from bias in measurement of outcomes because of non-blinded outcome assessors.(31,41) There was no evidence of publication bias in any of the included studies (Figure S3).”
ResultGLP-1-based therapeutics for cardiorenal protection in metabolic diseases
Apperloo, E. M., Heerspink, H. J. L., van Raalte, D. H., & Muskiet, M. H. A. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf110 · Cited by 25
Impact of intentional weight loss on diabetic kidney disease
Holland, J. A., Martin, W. P., Docherty, N. G., & le Roux, C. W. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13813 · Cited by 21
“Cardiovascular disease is the leading cause of death in patients with DKD.”
BackgroundInfluentialRivera, F. B., Chin, M. N. C., Pine, P. L. S., Ruyeras, M. M. J., Galang, D. J. C., Gandionco, K. M., Morales, B. L. F. D., Climaco, Z. M. V., Bantayan, N. R. B., Magalong, J. V., et al. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2442027 · Cited by 19
“This result is consistent with larger trials, including HARMONY 2 35 , HARMONY 3 40 , and LIRA-RENAL, 34 which also reported no meaningful changes in TG levels with GLP-1 RA treatment.”
Vedtofte, L., Knop, F. K., & Vilsbøll, T. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1288715 · Cited by 19
“Additionally, IDegLira is now approved for use in patients with moderate renal impairment following completion of the LIRA-RENAL trial [53].”
BackgroundCurrent therapeutic approaches in the management of hyperglycemia in chronic renal disease
Garla, V. V., Yanes-Cardozo, L. L., & Lien, L. F. (2017) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-017-9416-1 · Cited by 19
“66%with no difference in hypoglycemic episodes [55].”
Cope, R. J., Fischetti, B., Kavanagh, R., Lepa, T. M., & Sorbera, M. A. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2342 · Cited by 17
Mosenzon, O., Miller, E. M., & Warren, M. L. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1800286 · Cited by 16
Tsai, S., & Chen, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133152 · Cited by 16
“In the LIRA-RENAL trial for type 2 DM [47], no pati nts were enrolled if their GFR was less than 30 mL/min.”
MethodPioneering oral peptide therapy for patients with type 2 diabetes
Nauck, M. A., & Meier, J. J. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30182-2 · Cited by 15
New Glucose-Lowering Agents for Diabetic Kidney Disease
de Vos, L. C., Hettige, T., & Cooper, M. E. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2018.01.002 · Cited by 17
Luo, Y. L., Lü, K., Liu, G., Wang, J., Laurent, I., & Zhou, X. (2018) · Clinical Drug Investigation · doi:10.1007/s40261-018-0707-4 · Cited by 18
Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes
Mosenzon, O., Schechter, M., & Leibowitz, G. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.04.005 · Cited by 16
Efficacy and Safety of GLP-1 Receptor Agonists Across the Spectrum of Type 2 Diabetes Mellitus
Leiter, L. A., & Nauck, M. A. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-103969 · Cited by 16
GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01036-y · Cited by 22
Natale, P., Green, S. C., Tunnicliffe, D. J., Pellegrino, G., Toyama, T., & Strippoli, G. F. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015849.pub2 · Cited by 40
Sourij, H., Aberer, F., Antlanger, M., Brix, J., Cejka, D., Clodi, M., Edlinger, R., Eller, K., Horn, S., Kaser, S., et al. (2016) · Wiener klinische Wochenschrift · doi:10.1007/s00508-016-0992-y · Cited by 14
Zobel, E. H., von Scholten, B. J., Lindhardt, M. K., Persson, F., Hansen, T. W., & Rossing, P. R. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.09.016 · Cited by 16
Self-citationUrinary Proteome Differences in Patients with Type 2 Diabetes Pre and Post Liraglutide Treatment
Rafiullah, M., Benabdelkamel, H., Masood, A., Ekhzaimy, A. A., Musambil, M., Joy, S. S., & Alfadda, A. A. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45020092 · Cited by 14
“In a clinical trial, 26-week treatment with liraglutide did not change the renal function in the LIRA-RENAL trial [26].”
Gewehr, M. C. F., Silvério, R., Neto, J. C. R., Lira, F. S., Reckziegel, P., & Ferro, E. S. (2020) · Molecules · doi:10.3390/molecules25051093 · Cited by 15
Alobaid, S. M., Alshahrani, R. M., Alonazi, A. S., Alrasheed, N. M., Alamin, M. A., Alshammari, T. K., Bin Dayel, A. F., Elnagar, D. M., Alotaibi, R. R., Almuthnabi, L. A., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17030374 · Cited by 13
“The LEADER trial highlighted lower rates of cardiovascular death in patients with T2DM on liraglutide [26].”
BackgroundGeorge, J., Lobkovich, A. M., Nardolillo, J. A., Farhat, N., Kolander, S., & Thomas, E. (2022) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxac046 · Cited by 13
Can Newer Anti-Diabetic Therapies Delay the Development of Diabetic Nephropathy?
Aziz, S., Ghadzi, S. M. S., Sulaiman, S. A. S., Hanafiah, N. H. M., & Harun, S. N. (2021) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/jpbs.jpbs_497_21 · Cited by 13
“[33] The trial to evaluate cardiovascular and other long‑term outcomes with semaglutide in subjects with type 2 diabetes (SUSTAIN‑6) of 3,297 T2DM patients with cardiovascular risk, was conducted on patients randomly allocated to either receive semaglutide (at the dose of 0.5 or 1 mg once weekly)…”
InfluentialAlbiglutide for the management of type 2 diabetes
Rendell, M. (2017) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1419061 · Cited by 15
Cui, X., Meng, Q., Chu, Y., Gu, X., Tang, Y., Zhou, F. L., Fei, Y., Fu, J., & Han, J. D. J. (2016) · RSC Advances · doi:10.1039/c6ra22648e · Cited by 12
Liu, W., Yu, J., Tian, T., Miao, J., & Shang, W. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7577 · Cited by 12
Wu, H., Lu, Z., Chen, R., Cai, Q., Wang, M., Zhang, L., & Zhu, Z. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1098032 · Cited by 15
Osumili, B., Sapin, H., Yang, Z., Ranta, K., Paik, J. S., & Blüher, M. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01728-5 · Cited by 16
Chen, J.-J., Hsu, C., Hung, C., Liang, C., Su, K., Carvalho, A. F., Stubbs, B., Chen, Y.-W., Chen, T., Lei, W., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18050735 · Cited by 14
New Therapeutic Strategies for Type 2 DiabetesCME
Yehya, A., & Sadhu, A. (2018) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-14-4-281 · Cited by 13
Lin, C., Cai, X., Yang, W., Lv, F., Nie, L., & Ji, L. (2020) · BMC Medicine · doi:10.1186/s12916-020-01787-4 · Cited by 12
Cox, E. J., Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2020) · US Endocrinology · doi:10.17925/use.2020.16.2.80 · Cited by 10
“However, shorter treatment duration (26 weeks) with liraglutide did not demonstrate a beneficial effect on eGFR decline, perhaps due to insufficient observation time.(21)”
BackgroundAlqifari, S. F., Komi, O. A., Esmail, A., Alkhawami, K., Yousri, S., Muqresh, M. A., Alharbi, N., Khojah, A. A. A., Aljabri, A. M., Allahham, A., et al. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i3.331 · Cited by 11
Kheira, H. S., El‐Sayed, G., & El‐Adl, M. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150337 · Cited by 10
Bellos, I., Marinaki, S., Λάγιου, Π., & Benetou, V. (2024) · Biomolecules · doi:10.3390/biom15010039 · Cited by 12
Zobel, E. H., von Scholten, B. J., Hansen, T. W., Persson, F., Rasmussen, S., Wolthers, B. O., & Rossing, P. R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14578 · Cited by 9
“However, we chose a cut-off of 0, as eGFR was stable during 26 weeks of treatment with a GLP-1RA in the PIONEER 5 study(23) and the LIRA-RENAL study.(24) The mean 286 ZOBEL ET AL.”
MethodSelf-citationCases, A. (2023) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2023.09.003 · Cited by 16
Zobel, E. H., von Scholten, B. J., Goldman, B., Persson, F., Hansen, T. W., & Rossing, P. R. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13638 · Cited by 10
“HbA1c, body weight, SBP, LDL-cholesterol and UACR were measured and eGFR was calculated (based on the Modification of Diet in Renal Disease [MDRD] formula) at baseline, at regular intervals during the trial, and after 26 weeks of treatment, using routine methods.(6) UACR was calculated as the mean of the morning urine…”
MethodSelf-citationMallik, R., Ali, O., Casabar, M., Mukuba, D., Byrne, C., McCafferty, K., Yaqoob, M., & Chowdhury, T. A. (2023) · Diabetic Medicine · doi:10.1111/dme.15057 · Cited by 11
Overhydration: A cause or an effect of kidney damage and how to treat it
Szymczak, A., Kusztal, M. A., & Krajewska, M. (2021) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/132035 · Cited by 9
Guja, C., Frías, J. P., Suchower, L. J., Hardy, E., Marr, G., Sjöström, C. D., & Jabbour, S. A. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00815-z · Cited by 10
Mali, N., Feng, S., Ge, J., Fan, W., Zhang, J., & Ma, J. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01006-6 · Cited by 14
Dril, E. V., Allison, M., & Schumacher, C. (2022) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2022.100163 · Cited by 11
Ayers, D., Kanters, S., Goldgrub, R., Hughes, M., Kato, R., & Kragh, N. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1345730 · Cited by 12
Hsu, C., Zeng, B., Liang, C., Zeng, B., Hung, C., Stubbs, B., Chen, Y., Lei, W., Chen, J.-J., Chen, P., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178202 · Cited by 12
Soliman, A. R., Saleem, H. M. E., Meligi, A. A. H. E., Naguib, M., Mohamed, R. S., Abdelaziz, G. R., Rakha, M., Abdelghaffar, S., Hamed, A. E., Hammad, H., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01564-w · Cited by 10
“The LIRA-RENAL and LEADER RCTs also highlighted that Liraglutide slowed the onset and progression of CKD [152, 153].”
Zhang, J., Guan, X., Kong, M.-W., Xia, M., Yu, Y., & Zhang, C. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156433 · Cited by 9
Tseng, P., Zeng, B., Hsu, C.-W., Sun, C., Suen, M., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01750-x · Cited by 9
GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2022) · Kidney and Dialysis · doi:10.3390/kidneydial2030034 · Cited by 7
Boye, K. S., Mody, R., Wu, J., Lage, M. J., Botros, F. T., & Woodward, B. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.07.002 · Cited by 7
Neto, J. A. D. O. N., Yariwake, V. Y., Câmara, N. O. S., & Andrade‐Oliveira, V. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1248757 · Cited by 8
Wali, A. F., Rangraze, I. R., Khan, S. S., Mufti, U., El‐Tanani, M., & Rizzo, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1736380 · Cited by 7
Chatzis, D., Kolokathis, K., Magounaki, K., Chatzidakis, S., Avramidis, K., Leopoulou, M., Angelopoulos, T. P., & Doupis, J. (2021) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2021.17.2.92 · Cited by 8
“The LIRA-RENAL12 randomized controlled trial demonstrated that patients on linagliptin presented low levels of albuminuria and glycated haemoglobin A1c (HbA1c).(12,17) Remarkably, in the SAVOR-TIMI 53, TECOS, VERIFY and EXAMINE trials, the patients treated with saxagliptin, sitagliptin, vildagliptin and alogliptin pre…”
BackgroundYarlagadda, C., Abutineh, M., Reddy, A. J., Landau, A. B., Travis, L. M., Perrone, C. G., Idriss, A., & Patel, R. P. (2023) · Cureus · doi:10.7759/cureus.36438 · Cited by 7
Kaplan, H., Amod, A., Zyl, F. H. V., Reddy, J., van Tonder, A., Tsymbal, E., & McMaster, A. (2019) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/16089677.2019.1608053 · Cited by 8
Current status of Liraglutide delivery systems for the management of type 2 diabetes mellitus
Chatterjee, R., Galave, V. S. B., & Jindal, A. B. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01965-y · Cited by 7
Li, Y., Hu, Y., Huyan, X., Chen, K., Li, B., Gu, W., & Mu, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1003263 · Cited by 7
Luo, C., He, D., Yang, H., Zhu, C., Zhu, J., & Hu, Z. (2022) · African Health Sciences · doi:10.4314/ahs.v22i3.28 · Cited by 6
The safety of albiglutide for the treatment of type 2 diabetes
Rendell, M. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1351538 · Cited by 6
Renal hemodynamic changes in patients with type 2 diabetes and their clinical impact
Saulnier, P., & Bjornstad, P. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104175 · Cited by 7
The effect of GLP-1 receptor agonist and SGLT2 inhibitor on infection risk: network meta-analysis
Zeng, B.-S., Chen, J.-J., Hsu, C.-W., Hung, C.-M., Zeng, B., Suen, M., Yang, W.-C., Wang, H.-Y., Shiue, Y.-L., Su, K.-P., et al. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.01.014 · Cited by 7
Sidra, F. N. U., Agarwal, S., Pastor, P. L., Xie, D., Li, X., & Lingvay, I. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108925 · Cited by 6
THE POSSIBILITY OF REDUCING CARDIOVASCULAR RISK IN PATIENTS WITH DIABETES MELLITUS TYPE 2
Editorial, A. (2017) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2017-9-99-103 · Cited by 4
Alanazi, N., & Ghoraba, M. (2020) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_361_20 · Cited by 5
Cai, Y., Liu, F.-H., Sun, J., & Lin, C. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.11.016 · Cited by 4
Rico-Fontalvo, J. E., Daza-Arnedo, R., Elbert, A. E., Correa‐Rotter, R., Diná-Batlle, E., Lorca, E., de Moraes, T. P., Sánchez-Polo, V., & Builes-Montaño, C. E. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01854-8 · Cited by 6
“The dedicated LIRA‑RENAL trial [31] further evaluated liraglutide in patients with T2D and moderate renal impairment (eGFR 30–59 mL/ min/1.73 m 2 ).”
InfluentialNewer and novel antidiabetic drug classes across the cardiovascular–kidney–metabolic continuum
Stefanakis, K., Karakasis, P., Vasdeki, D., Popovic, D. S., Patoulias, D., Rizzo, M., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag022 · Cited by 6
Tommerdahl, K. L., Kula, A. J., & Bjornstad, P. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2203319 · Cited by 6
WITHDRAWN: Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.
Lovshin, J. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.02.003 · Cited by 3
RetractedCardiovascular and Renal Outcomes of Incretin-based Therapies: A Review of Recent Clinical Trials
Kyriakos, G., Quiles-Sánchez, L. V., Garmpi, A., Farmaki, P., Kyre, K., Gkogkos, S., Savvanis, S., & Memi, E. (2019) · Current Cardiology Reviews · doi:10.2174/1573403x15666190603111056 · Cited by 3
Combined medical strategies for the management of type 2 diabetes mellitus and obesity in adults
Tarazi, M. S., Touhamy, S., Tchang, B. G., & Shukla, A. P. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1942841 · Cited by 4
Antidiabetic Medication-Induced Acute Interstitial Nephritis: Case Report and Literature Search
Chaudhury, N., Liarakos, A. L., Gopalakrishnan, K., Ayub, W., Murthy, N., & Rao, R. (2021) · British Journal of Diabetes · doi:10.15277/bjd.2021.321 · Cited by 4
Deng, Y., Ghamsari, F., Lu, A., Yu, J., Zhao, L., & Kho, A. (2022) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2022.100309 · Cited by 4
Management of type 2 Diabetes in patients with Chronic Kidney Disease
Bansal, B. (2017) · Archives of Clinical Nephrology · doi:10.17352/acn.000026 · Cited by 4
Efficacy and safety of liraglutide added to insulin therapy in elderly patients with type 2 diabetes
Tonoike, M., Chujo, D., & Noda, M. (2018) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.43 · Cited by 3
Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease
Niezen, S., del Castillo, H. D., Castaner, L. A. M., & Fornoni, A. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.72 · Cited by 2
Busch, C. B. E., Rubingh, J., van Baar, A. C. G., Nieuwdorp, M., & Bergman, J. J. G. H. M. (2025) · BMJ Nutrition Prevention & Health · doi:10.1136/bmjnph-2024-001006 · Cited by 4
Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed
Martínez‐Castelao, A., Górriz, J. L., Fernández‐Fernández, B., Soler, M. J., & Navarro‐González, J. F. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14238326 · Cited by 4
San, K., Fogel, J., & Khazron, D. (2023) · Southern Medical Journal · doi:10.14423/smj.0000000000001511 · Cited by 2
Use of GLP-1 receptor agonists in patients with T2DM and chronic kidney disease
Aldrich, S., & Ashjian, E. J. (2019) · The Nurse Practitioner · doi:10.1097/01.npr.0000553396.65976.bb · Cited by 3
Wang, Y., Feng, L., Wang, Y., Li, B., Liang, N., Song, X., Qin, J., Zhang, M., & Li, Y. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2620155 · Cited by 2
Zhu, X., Wang, X., Zhang, P., Yang, Z., Zhao, N., Li, J., Shi, Y., Zhao, Y., & Ma, J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1750615 · Cited by 1
Efficacy and Safety of GLP-1 Agonists in Chronic Kidney Disease: A Case Series
Awdishu, L., & Morello, C. M. (2018) · Clinical Medical Reviews and Case Reports · doi:10.23937/2378-3656/1410242 · Cited by 1
Assunção, I. L., Gonzalez, G. M. M., da Silva, V. M., de Carvalho, C. S. V., Machado, A. G. M., dos Santos, V. M., Pascoal, G. D. A., Forest, G. O., de Sousa, J. C. F., Fonseca, I. A. R., et al. (2021) · Research Society and Development · doi:10.33448/rsd-v10i16.23517 · Cited by 1
Demidova, T. Y., Titova, V. V., & Скуридина, Д. В. (2023) · FOCUS Endocrinology · doi:10.15829/2713-0177-2023-4-23 · Cited by 1
GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Game Charger in the Field?
Doumani, G., Theofilis, P., Tsimihodimos, V., & Kalaitzidis, R. (2024) · Life · doi:10.3390/life14111478 · Cited by 5
Zinych, О. В., Kushnariova, N. M., Ковальчук, А., Prybila, O. V., Shyshkan-Shyshova, К. О., Gurina, N. M., & Korpachev, V. V. (2016) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.7.79.2016.86417 · Cited by 1
Agonistes du récepteur du GLP-1 et fonction rénale chez le diabétique de type 2
Meyer, L., & Bahougne, T. (2017) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(17)30067-6 · Cited by 1
Blonde, L., & Fonseca, V. A. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0293 · Cited by 2
Inflammatory Mechanisms in Diabetic Kidney Disease
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R. (2020) · Springer eBooks · doi:10.1007/978-3-030-53370-0_32 · Cited by 1
Kavyasree, A., Geetha, P. V., & Shanmugasundaram, P. (2021) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2021.00405 · Cited by 1
GLP-1-receptoragonista-kezelés diabeteses vesebetegségben
Fülöp, G. Á., Dezső, L., & Wittmann, I. (2021) · Diabetologia Hungarica · doi:10.24121/dh.2021.7 · Cited by 1
Howse, P. M., Chibrikova, L., Twells, L., Barrett, B. J., & Gamble, J. (2016)
Halimi, S. (2017) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(17)30052-4
藤田, 浩., & 高嶋, 悟. (2017) · 糖尿病 · doi:10.11213/tonyobyo.60.576
Medina, A. G. M., Olivares, C., Salinas, C., Rosselli, C., Barón, R. A., Ocampo, D., Tovar, A. P., Rincón, O., Villegas, I., & Fortich, Á. (2017) · Alad · doi:10.24875/alad.17000236
Solano, J. N., & Chen-Ku, C. H. (2020) · Acta Médica Costarricense · doi:10.51481/amc.v60i2.997 · Cited by 1
Nedogoda, S. V. (2018) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2018-4-89-92
The privileged position of glp-1 in diabetic nephropathy
Kunz-Martínez, W., & Pacheco, A. I. P. (2018) · Endocrinology&Metabolism International Journal · doi:10.15406/emij.2018.06.00182
Metadata
- Authors
- Davies, M. J., Bain, S. C., Atkin, S. L., Rossing, P., Scott, D., Shamkhalova, M. S., Bosch-Traberg, H., Syrén, A., & Umpierrez, G. E.
- Affiliations
- University of Leicester (GB)
- Swansea University (GB)
- Weill Cornell Medical College in Qatar (QA)
- Steno Diabetes Center, Gentofte, Denmark
- Clinical Research Development Associates, Rosedale, NY
- Department of Diabetic Nephropathy, Endocrinology Research Centre, Moscow, Russia
- Novo Nordisk A/S, Søborg, Denmark
- Novo Nordisk (Denmark) (DK)
- Emory University (US)
- Corresponding author
- Davies, Melanie J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-12-17
- Volume
- 39
- Issue
- 2
- Pages
- 222-230
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2236659707
- Cited by
- 235
- References
- 35
- Citations by year
- 2026: 19 · 2025: 20 · 2024: 17 · 2023: 28 · 2022: 18 · 2021: 19 · 2020: 24 · 2019: 22 · 2018: 28 · 2017: 24 · 2016: 16
- FWCI
- 19.71
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- cc-by
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Leicester Research Archive (University of Leicester) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- liraglutide, type 2 diabetes, renal dysfunction, glycemic control, HbA1c, fasting blood glucose, weight loss, renal function, lipase, hypoglycemia, gastrointestinal adverse effects, GLP-1 receptor agonists, GIP receptor agonist, GIP/GLP-1 receptor agonist
- MeSH terms
- Liraglutide, Adolescent, Adult, Aged, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Gastrointestinal Tract, Renal Insufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.